Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) - Net Assets
Based on the latest financial reports, Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) has net assets worth TL2.93 Billion TRY (≈ $65.61 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (TL3.59 Billion ≈ $80.42 Million USD) and total liabilities (TL661.10 Million ≈ $14.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Meditera Tibbi Malzeme Sanayi ve Ticaret (MEDTR) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | TL2.93 Billion |
| % of Total Assets | 81.59% |
| Annual Growth Rate | 60.21% |
| 5-Year Change | 414.5% |
| 10-Year Change | N/A |
| Growth Volatility | 56.7 |
Meditera Tibbi Malzeme Sanayi ve Ticaret AS - Net Assets Trend (2018–2025)
This chart illustrates how Meditera Tibbi Malzeme Sanayi ve Ticaret AS's net assets have evolved over time, based on quarterly financial data. Also explore Meditera Tibbi Malzeme Sanayi ve Ticaret total assets for the complete picture of this company's asset base.
Annual Net Assets for Meditera Tibbi Malzeme Sanayi ve Ticaret AS (2018–2025)
The table below shows the annual net assets of Meditera Tibbi Malzeme Sanayi ve Ticaret AS from 2018 to 2025. For live valuation and market cap data, see Meditera Tibbi Malzeme Sanayi ve Ticaret (MEDTR) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | TL2.93 Billion ≈ $65.61 Million |
+0.14% |
| 2024-12-31 | TL2.93 Billion ≈ $65.52 Million |
+36.93% |
| 2023-12-31 | TL2.14 Billion ≈ $47.85 Million |
+140.84% |
| 2022-12-31 | TL887.08 Million ≈ $19.87 Million |
+55.80% |
| 2021-12-31 | TL569.37 Million ≈ $12.75 Million |
+162.20% |
| 2020-12-31 | TL217.15 Million ≈ $4.86 Million |
+71.68% |
| 2019-12-31 | TL126.49 Million ≈ $2.83 Million |
+16.99% |
| 2018-12-31 | TL108.11 Million ≈ $2.42 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Meditera Tibbi Malzeme Sanayi ve Ticaret AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2534.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | TL645.37 Million | 22.21% |
| Other Components | TL2.26 Billion | 77.79% |
| Total Equity | TL2.91 Billion | 100.00% |
Meditera Tibbi Malzeme Sanayi ve Ticaret AS Competitors by Market Cap
The table below lists competitors of Meditera Tibbi Malzeme Sanayi ve Ticaret AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Progress-Werk Oberkirch AG
XETRA:PWO
|
$80.00 Million |
|
Case Group AB
ST:CASE
|
$80.01 Million |
|
Investigator Resources Ltd
AU:IVR
|
$80.04 Million |
|
meerecompany Incorporated
KQ:049950
|
$80.04 Million |
|
Arena Bilgisayar Sanayi ve Ticaret AS
IS:ARENA
|
$79.96 Million |
|
Games Workshop Group PLC
LSE:GAW
|
$79.94 Million |
|
Daebongls.Co.Ltd
KQ:078140
|
$79.87 Million |
|
Thac Ba Hydropower JSC
VN:TBC
|
$79.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Meditera Tibbi Malzeme Sanayi ve Ticaret AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,918,879,448 to 2,905,737,069, a change of -13,142,379 (-0.5%).
- Net loss of 9,271,831 reduced equity.
- Dividend payments of 37,766,347 reduced retained earnings.
- Share repurchases of 12,310,434 reduced equity.
- Other factors increased equity by 46,206,233.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | TL-9.27 Million | -0.32% |
| Dividends Paid | TL37.77 Million | -1.3% |
| Share Repurchases | TL12.31 Million | -0.42% |
| Other Changes | TL46.21 Million | +1.59% |
| Total Change | TL- | -0.45% |
Book Value vs Market Value Analysis
This analysis compares Meditera Tibbi Malzeme Sanayi ve Ticaret AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.23x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 65.27x to 1.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | TL0.46 | TL30.00 | x |
| 2019-12-31 | TL0.56 | TL30.00 | x |
| 2020-12-31 | TL1.82 | TL30.00 | x |
| 2021-12-31 | TL4.78 | TL30.00 | x |
| 2022-12-31 | TL7.44 | TL30.00 | x |
| 2023-12-31 | TL18.09 | TL30.00 | x |
| 2024-12-31 | TL24.53 | TL30.00 | x |
| 2025-12-31 | TL24.42 | TL30.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Meditera Tibbi Malzeme Sanayi ve Ticaret AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.32%
- • Asset Turnover: 0.80x
- • Equity Multiplier: 1.24x
- Recent ROE (-0.32%) is below the historical average (17.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 22.83% | 6.26% | 0.98x | 3.72x | TL7.02 Million |
| 2019 | 18.97% | 5.49% | 1.05x | 3.28x | TL6.02 Million |
| 2020 | 27.83% | 16.82% | 1.05x | 1.57x | TL38.71 Million |
| 2021 | 29.45% | 44.61% | 0.52x | 1.26x | TL110.76 Million |
| 2022 | 33.54% | 36.85% | 0.73x | 1.24x | TL208.48 Million |
| 2023 | 1.75% | 1.78% | 0.77x | 1.28x | TL-175.49 Million |
| 2024 | 3.29% | 3.51% | 0.75x | 1.26x | TL-195.77 Million |
| 2025 | -0.32% | -0.32% | 0.80x | 1.24x | TL-299.85 Million |
Industry Comparison
This section compares Meditera Tibbi Malzeme Sanayi ve Ticaret AS's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $891,534,193
- Average return on equity (ROE) among peers: -24.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) | TL2.93 Billion | 22.83% | 0.23x | $79.96 Million |
| Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) | $1.55 Billion | -14.11% | 0.15x | $55.09 Million |
| Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) | $231.70 Million | -34.45% | 0.46x | $145.30 Million |
About Meditera Tibbi Malzeme Sanayi ve Ticaret AS
Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi manufactures and sells medical devices in Turkey. The company offers two-way and single-line Infusion Systems; Chemotherapy Preparation and Administration Systems, such as medoconco automated drug preparation, diana semi-automatic drug dispensing, and ICU medical chemotherapy drug delivery systems; and respiratory systems products, includin… Read more